《Recent Patents On Anti-cancer Drug Discovery》雜志的最新年發文量為38篇。
年發文量趨勢圖
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在腫瘤學領域的學術影響力。
該刊聚焦于醫學-腫瘤學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 約3.0個月 。
Recent Patents On Anti-cancer Drug Discovery 雜志發文統計
文章名稱引用次數
- Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins22
- PARP Inhibitors in Ovarian Cancer19
- Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents16
- The Application of lncRNAs in Cancer Treatment and Diagnosis16
- Advances in the Discovery of Anthraquinone-Based Anticancer Agents15
- Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy14
- PARP Inhibitors in Epithelial Ovarian Cancer12
- Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Micro-environment7
- Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches7
- HMGA and Cancer: A Review on Patent Literatures6
國家/地區發文量
- CHINA MAINLAND27
- Italy17
- Iran11
- USA9
- India7
- Pakistan6
- Russia4
- Canada3
- Romania3
- South Korea3
